Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
83 hedge funds and large institutions have $210M invested in Jounce Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 31 closing their positions.
83% more call options, than puts
Call options by funds: $2.1M | Put options by funds: $1.15M
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
12% less funds holding
Funds holding: 94 → 83 (-11)
35% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 31
69% less capital invested
Capital invested by funds: $669M → $210M (-$459M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.25M |
| 2 |
BlackRock
New York
|
+$3.65M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.49M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.95M |
| 5 |
Two Sigma Investments
New York
|
+$2.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$43M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$11.7M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$11M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.97M |
| 5 |
CC
Casdin Capital
New York
|
-$3.75M |
JNCE Hedge Fund Activity: Q2 2018 in Review
83 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2018, worth a combined $210M — down 69% from $669M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of JNCE and 20 opened new positions — a net loss of 11 holders — while 22 trimmed existing stakes and 28 added.
The largest buyer was Millennium Management, adding an estimated $6.25M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $43M sold.
- 83 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2018, down from 94 in Q1 2018.
- Funds reported $210M of Jounce Therapeutics, Inc. Common Stock stock for Q2 2018, down 69% quarter-over-quarter.
- 20 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2018 and 31 closed out, a net change of -11 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q2 2018 was Millennium Management, an estimated $6.25M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2018 was PFM Health Sciences, an estimated $43M sold.
Based on aggregated 13F filings for Q2 2018.